{"id":"W2108984264","doi":"10.1016/s0140-6736(13)60594-2","title":"Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial","year":2013,"lang":"en","type":"article","venue":"The Lancet","topic":"Spondyloarthritis Studies and Treatments","field":"Medicine","cited_by":798,"is_retracted":false,"has_abstract":false,"ca_institutions":"Memorial University of Newfoundland","funders":"Janssen Research and Development","keywords":"Ustekinumab; Psoriatic arthritis; Medicine; Placebo; Double blind; Internal medicine; Arthritis; Dermatology; Rheumatoid arthritis; Pathology; Alternative medicine; Adalimumab","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02092396615650787,"score_gpt":0.2785360004406129,"score_spread":0.257612034284105,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}